

PATENT SPECIFICATION

(11) 1 346 871

1 346 871

(21) Application No. 24805/72 (22) Filed 25 May 1972
 (31) Convention Application No. 95495 (32) Filed 3 Nov. 1971 in
 (33) United States of America (US)
 (44) Complete Specification published 13 Feb. 1974
 (51) International Classification C07C 171/04; A61K 27/00
 (52) Index at acceptance

C2C 170—189—276 171—191—280 172—179—181
 172—194—284 174—198—272 17X—191—278
 1E1K3 200 213 215 220 226 227 22X 22Y 246
 250 251 252 25Y 292 29X 29Y 30Y 314 31Y 320
 321 322 323 32Y 332 338 340 341 342 34Y 351
 355 35X 360 361 362 364 365 366 367 368 36Y
 371 373 37Y 387 388 389 3A10E1 3A7V4A3
 3A7V4E1 3A7V4L 401 40Y 509 50Y 575 576 57Y
 583 593 603 612 620 623 624 625 626 627 628
 62X 633 634 638 63X 643 648 64X 650 652 658
 65X 662 665 66X 675 678 70X 70Y 790 79Y KB
 KD KH KK KM KN KP KZ RE RF UJ



(54) 11-DEOXOGLYCYRRHETINIC ACID AMIDES USEFUL AS ANTIULCER AGENTS

(71) We, PFIZER INC., a Corporation organized under the laws of the State of Delaware, United States of America, of 235, East 42nd Street, New York 17, State of New York, United States of America, do hereby declare the invention, for which we pray that a Patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: —

This invention relates to novel derivatives of glycyrrhetic acid and to their use as antiulcer agents. More specifically, it relates to amide derivatives of 11-deoxoglycyrrhetic acid and its 3-alkanoyl derivatives which are useful antiulcer agents wherein the amide is derived from ammonia, an alkanolamine, a dialkanolamine, a cyclic amine, a primary or secondary amine, an ω -hydroxyalkyl alkylene diamine, an ω -[bis(hydroxyalkyl)alkylene diamine, or an amino acid.

Chronic gastric and duodenal ulcers, collectively known as peptic ulcers, are a common affliction for which a variety of treatments have been developed. The treatment depends upon the severity of the ulcer and may range from dietary and medical (drug) treatment to surgery. A wide variety of drugs have been used to treat ulcers, the most recent of which to gain widespread attention is carbenoxolone sodium, the disodium salt of the hemisuccinate of glycyrrhetic acid. It is reported to prevent formation of and to accelerate healing of gastric ulcers in animals, including humans, ("Carbenoxolone Sodium: A symposium," J. M. Robson and F. M. Sullivan, Eds., Butterworths, London, 1968). However, its use is accompanied by undesirable aldosterone-like side effects, such as marked anti-diuretic and sodium -retaining activity, and, oftentimes, potassium loss such that continued therapy with this agent often leads to hypertension, muscle weakness and, ultimately, congestive heart failure.

Carbenoxolone sodium is almost wholly absorbed in the stomach and is not effective against duodenal ulcers except when administered as a specially formulated capsule which enables its transport to the desired site.

A more effective treatment of peptic ulcers is therefore desirable. One which will effectively act upon ulcers in the duodenum as well as upon gastric ulcers without the need of special formulation and minimizes the aldosterone-like side effects of carbenoxolone is especially desirable.

Glycyrrhetic acid, esters, 3-acyloxy derivatives, salts and amides thereof are known to exhibit pharmaceutical properties, British Patent 628,443 (August 14, 1963) reports glycyrrhetic acid to be an anti-inflammatory, analgesic and antipyretic agents. U.S. 3,070,623 (December 25, 1962) describes hemi-esters of glycyrrhetic acid, including the hemisuccinate (also known as carbenoxolone sodium), as anti-inflammatory agents. U.S. 3,070,624 (December 25, 1962) teaches basic esters of the carboxy group

BEST AVAILABLE COPY

5 at the 20-position of glycyrrhetic acid which exhibit anti-inflammatory properties and inhibit the action of steroids and steroid metabolism. Anti-inflammatory and analgesic properties are reported for amino acid salts of glycyrrhetic acid in Japanese Patent 32798/69, published October 27, 1965. French Patent 215
 10 5 CAM/5544M, published July 19, 1968, discloses hypoglycemic activity for glycyrrhetic acid and its methyl ester. Salts of glycyrrhetic acid and its hemi-esters with aluminium, zinc, bismuth and metals of groups II-A and VIII of the Periodic
 15 Chart of the Elements are reported in Belgian Patent 628,444, published February 4, 1963, to be of value in treating digestive disorders such as gastric acidosis, inflammation and ulcers.


15 10 Amides of glycyrrhetic acid and its 3-acyl derivatives useful as anti-inflammatory agents are described in a number of patents. Cyclic amides, e.g., the piperazine, N-acylpiperazines, N-carbalkoxypiperazines, are described in Belgian Patent 753,773, granted July 28, 1969. The N-(lower alkyl)piperazines, piperide and morpholide are disclosed in Japanese Patent 26,300/67, published December 13, 1967, (C.A. 69, 44067t, 1968). Additionally, simple amides, e.g., the di(lower alkyl)substituted amides, are described in this Japanese patent. U.S. Patent 3,412,084 (November 19, 1968) teaches alkyl, cycloalkyl, aralkyl and aryl substituted amides of glycyrrhetic acid as well as heterocyclic amides thereof all of which are reported to be anti-inflammatory agents of low toxicity. Dialkylaminoalkyl substituted amides of glycyrrhetic acid are described by Adanin *et al.*, Zh. Obshch. Khim. 37, 1063-65 (1967) (C.A. 68, 22087q, 1968). Alkyolamine condensates of glycyrrhetic acid useful as anti-inflammatory agents in cosmetics are reported in Japanese Patent 8382/67, published November 4, 1967.

20 15 25 A variety of derivatives of glycyrrhetic acid and 11-deoxoglycyrrhetic acid are described by Dean *et al.*, J. Pharm. Pharmac. 19, 682-9 (1967); including the hemi-succinates of methyl glycyrrhetinate, glycyrrhetinamide and 11-deoxoglycyrrhetic acid; the 3-acetyl derivatives of glycyrrhetinamido-ortho- and para-benzoic acids; and N-(glycyrrhetinyl)glycine(glycyrrhetinic acid).

30 20 25 30 Various derivatives of 11-deoxoglycyrrhetic acids useful as intermediates are described by Ruzicka *et al.* in Helv. Chim. Acta 20, 1271 (1937) and 22, 197 (1939); Corey *et al.*, J. Am. Chem. Soc. 81, 1745 (1959) and Drefahl *et al.*, Ber. 94, 2015 (1961): the acetyl-, the methyl ester, the acetyl acid chloride, the acetyl methyl ester, the acetyl azide and the acetyl amide.


35 30 35 40 Groen *et al.*, Acta Med. Scand. Suppl. 312, 745-748 (1956) in a comparative study of the pharmacological activity of the adrenocortical steroids and glycyrrhetic acid noted that in order to retain activity in either class of compounds only a limited degree of structural variation is possible. They noted that "the activity seemed dependent on the presence of an 11-keto group." Vinogradov *et al.*, Khim. v Estestv. Nauk Sb. 40-6, 1965 (C.A. 65, 6136c, 1966) report the methyl ester of 11-deoxoglycyrrhetic acid gave rise to a sharp increase in the excretion of water and sodium by the kidneys in dogs. In rats, 11-deoxoglycyrrhetic relieved the action of deoxycorticosterone.

45 40 45 It has now been found that 11-deoxoglycyrrhetic acid amides of the formulae below are effective antiulcer agents:



I

and



II.

wherein R₁ is hydrogen, alkanoyl having from two to six carbon atoms or ω -carboxy- alkanoyl having a total of from four to five carbon atoms;

5 R_2 is hydrogen, alkyl having from one to four carbon atoms or hydroxyalkyl having from two to four carbon atoms;

R_3 is hydrogen, alkyl having from one to four carbon atoms, hydroxyalkyl having from two to four carbon atoms, ω -(hydroxyalkylamino)alkyl or ω -[bis(hydroxyalkyl)amino]alkyl both having from two to four carbon atoms in each alkyl moiety; or

10 R_2 and R_3 , when taken together with the nitrogen atom to which they are attached are piperazino, N-alkylpiperazino having from one to four carbon atoms in the alkyl moiety, N-(ω -hydroxalkyl)piperazino having from two to four carbon atoms in the alkyl moiety, N-(carbalkoxy)piperazino having from

15 one to four carbon atoms in the alkoxy moiety, pyrrolidino, piperidino or 2,6-dimethylpiperidino; with the proviso that when R_2 is alkyl or hydroxy-alkyl, R_3 is other than ω -(hydroxyalkylamino)alkyl or ω -[bis(hydroxyalkyl)-amino]-alkyl;

R_4 is hydrogen,
alkyl having from one to four carbon atoms,

mercaptomethyl,
2-methylthioethyl,
4-(α - β -imidezolyl)methyl

25 4-(or 5)-imidazolylmethyl, benzyl, 4-hydroxybenzyl.

*3,4-dihydroxybenzyl,
3,5-dibromo-4-hydroxybenzyl,*

30 carboxy, carballkoxy having from one to four carbon atoms in the alkoxy moiety,

ω-carboxyalkyl having from one to two carbon atoms in the alkyl moiety, ω-(carboxyalkoxy)alkyl having from one to four carbon atoms in the alkoxy

35 group and from one to two carbon atoms in the alkyl group, ω -aminoalkyl having from two to four carbon atoms in the alkyl moiety, ω -carboalkyl having from one to three carbon atoms in the alkyl

55 α -Carbamoylalkyl having from one to three carbon atoms in the alkyl moiety;
3-guanidino-propyl.

3-guanidinopropyl,
3-ureidopropyl, or
3-indolymethyl;

40 R₅ is hydroxy, alkoxy having from one to four carbon atoms, amino or dialkylamino having from one to four carbon atoms in each alkyl moiety;

Also included in this invention are the pharmaceutically-acceptable alkali metal salts (e.g. sodium and potassium) of these compounds which contain at least one carboxy

45 group; i.e. those wherein R_1 is ω -carboxyalkanoyl or R_5 is hydroxy or R_4 is carboxy or ω -carboxyalkyl; and the pharmaceutically-acceptable acid addition salts of those compounds in which the amide moiety has a basic group such as those wherein R_3 is ω -(hydroxyalkyl)amino)alkyl, ω -[bis(hydroxyalkyl)amino]alkyl or wherein R_4 is ω -aminoalkyl- or 3-guanidinopropyl- and those wherein NR_2R_3 is piperazine, N -(ω -hydroxyalkyl)piperazino or N -alkylpiperazino. Representative of the acid addition salts

are the hydrochloride, hydrobromide, sulfate, phosphate, nitrate, acetate, propionate, butyrate, citrate, gluconate, tartrate, benzoate, succinate, maleate, maleate and fumarate.

In addition to the alkali metal salts of these compounds of this invention containing a carboxy group, salts with metals such as the alkaline earth metals, especially calcium and magnesium, and with aluminium, zinc and bismuth and metals of group VIII of the Periodic Chart of the Elements are also included.

The novel products of this invention, that is all compounds of formulae I and II except those wherein R_3 is hydrogen, are prepared by acylation of the appropriate amine HNR_2R_3 or amino acid $R_3CH(NH_2)COR_3$ reactant with an acid halide (chloride or bromide) of 11-deoxoglycyrrhetic acid in which the 3-hydroxy group is suitably protected as, for example, by acylation with a monocarboxylic acid, anhydride or acid halide, or with the acid chloride of a dicarboxylic acid half-ester. Protection of the 3-hydroxy group is necessary to permit formation of the acid halide of 11-deoxoglycyrrhetic acid. The acid halides of the 3-acyl-11-deoxoglycyrrhetic acids are prepared by treating the 3-acyl-11-deoxoglycyrrhetic acids with excess thionyl chloride or bromide at from about room temperature to the boiling point of the thionyl halide and, subsequently, removing the excess thionyl halide. The favored acid halides are the acid chlorides since they provide satisfactory yields of desired product. The favored protecting group at the 3-hydroxy group is acetyl since it is easily removed by mild hydrolysis to regenerate the free hydroxy group.

Compounds of the above formulae within R_1 is an ω -carboxyalkanoyl group can be prepared from an alkyl ester thereof, preferably a methyl or ethyl ester, by means of lithium iodide in *N,N*-dimethylformamide at the reflux temperature. This treatment, of course, also hydrolyzes any ester group present in the amide moiety. Alternatively, an ω -carbobenzoxyalkanoyl derivative can be used in place of an ω -carboxyalkanoyl derivative. The benzyl group is easily removed by catalytic hydrogenation, e.g., with palladium on charcoal. This procedure has the advantage of permitting retention of alkyl ester groups in the amide moiety.

The 3-acyl-11-deoxoglycyrrhetic acid amides thus produced, in addition to being anti-inflammatory and antiulcer agents, serve as intermediates, particularly for the production of half esters with dicarboxylic acids. The 3-hydroxy group produced on hydrolysis is reacylated with a different acid (e.g., acid anhydride or halide), especially with a dicarboxylic acid, to produce a half-ester of the dicarboxylic acid, e.g., a hemisuccinate.

When the amide moiety (formulae I and II) contains an amino, hydroxy or mercapto group, such group must first be protected before acylation of the 3-hydroxy group. A suitable and convenient protecting group is the benzyl group since it is easily removed by hydrogenolysis. This group can be present in the HNR_2R_3 or $R_3CH(NH_2)COR_3$ reactant or be introduced into the 3-acyl-11-deoxoglycyrrhetic acid amide.

The compounds described herein are effective antiulcer agents via the intraperitoneal and oral routes of administration against gastric and duodenal ulcers. These products not only accelerate healing of such ulcers but also prevent formation of ulcers and decrease gastric acid output in animals, including humans. They can, therefore, be said to be useful for the control of gastric and duodenal ulcers. The incidence of side effects, e.g., aldosterone-like fluid retention and electrolyte disturbances, attendant with the use of many of the compounds of this invention is relatively low and is nonexistent with some of them. Particularly valuable in this respect are 1-(3 β -acetoxy-18 β -olean - 12 - en - 30 - oyl) - 4 - (2 - hydroxyethyl)piperazine; N - (2 - hydroxyethyl)-3 β - hydroxy - 18 β - olean - 12 - en - 30 - amide; and N - [3 - [bis - (2 - hydroxyethyl)amino]propyl] - 3 β -acetoxy-18 β -olean-12-en-30-amide.

The valuable products of this invention can be administered alone or in combination with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. For example, they can be administered orally in the form of tablets containing such excipients as polyvinylpyrrolidone, a Carbowax (registered Trade Mark, non-volatile, solid polyethylene glycols available from Carbide and Carbon Chemicals Corporation), especially Carbowax 6000, starch, milk sugar, etc. or in capsules alone or in admixture with the same or equivalent excipients. They may also be administered orally in the form of elixirs or oral suspen-

5 sions which may contain flavouring or coloring agents or be injected parenterally; that is, for example, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile solution which may be either aqueous such as water, isotonic saline, isotonic dextrose, Ringer's solution, or non-aqueous such as fatty oils of vegetable origin (cotton seed, peanut oil, corn, sesame) and other non-aqueous vehicles which will not interfere with the therapeutic efficiency of the preparation and are non-toxic in the volume or proportion used (glycerol, propylene glycol, sorbitol). Additionally compositions suitable for extemporaneous preparation of solutions prior to administration may advantageously be made. Such compositions may include liquid diluents, for example, propylene glycol, diethyl carbonate, glycerol, or sorbitol; buffering agents as well as local anesthetics and inorganic salts to afford desirable pharmacological properties.

10 For both oral and intraperitoneal administration, a dosage range of from about 150 mg. to about 300 mg. per day is effective. The dosage level can, with careful supervision, range up to as high as about two grams per day. Propylene glycol is a suitable and convenient carrier or diluent for intraperitoneal use. Carbowax 6000 is a favored excipient for oral use. Compositions containing from about 50% to about 90% by weight of polyvinylpyrrolidone or Carbowax 6000 are especially effective for oral administration. Higher or lower amounts of excipient can, of course, be used but appear to offer no advantages over these proportions. For intraperitoneal use, the polyvinylpyrrolidone formulations are suspended in carriers such as water or in saline solution containing 1% carboxymethylcellulose and 0.1% Tween 80 (registered Trade Mark, polyoxyethylene ethers of partial esters of fatty acids and hexitol anhydrides derived from sorbitol, available from Atlas Chemical Industries, Inc.). The water soluble products of this invention are conveniently administered in water solution.

15 25 The effectiveness of the products of this invention as antiulcer agents is determined by the stressed rat assay as follows.

Cold-Restraint Stressed Rat:

30 Non-fasted female rats (Charles River C-D strain) weighing 70—140 gms. are administered the drug or carrier (control animals) intraperitoneally (in saline containing 1% carboxymethylcellulose and 0.1% Tween 80) or orally (in water) three hours before being lightly anesthetized with ether and taped in the supine position to individual sheets of plexiglass, (registered Trade Mark). After recovery from the anesthesia, the restrained animals are positioned horizontally in a refrigerator maintained at 10—12°C. and three hours later sacrificed by cervical dislocation. The abdomen of each rat is opened, the pylorus clamped, the stomach inflated with saline via an oral tube, the esophagus clamped and the stomach excised. The stomachs are placed in a 0.4% formaldehyde solution for approximately 30 seconds to harden the outer layers and facilitate examination. Each stomach is then cut open along the greater curvature and the glandular portion (hind stomach) examined for damage. The number of gastric erosions, their severity and the color of the stomachs is recorded. The Mann-Whitney-Wilcoxon rank sum test is used to compare the medium number of gastric erosions in the control group with the median number of gastric erosions in each drug-treated group to determine if they are statistically different. (Dixon *et al.*, "Introduction to Statistical Analysis," 3rd Ed., McGraw-Hill Book Company, New York, pp. 344—347, 1969.)

35 40 45 Results thus obtained with carbenoxolone (Drug A) and 1-(3 β -acetoxy-18 β -olean-12-en-30-oyl)-4-(2-hydroxyethyl)piperazine hydrochloride (Drug B) are presented below.

TABLE I
Antiulcer Activity in Stressed Rat Assay

Drug ⁽¹⁾	Carrier ⁽²⁾	Route ⁽³⁾	20	30	40	60	80	160	320	640
A	distilled water	P.O.	—	—	No	—	No	No	No	No
A	saline	I.P.	No	Yes	Yes	Yes	Yes	—	—	—
B	distilled water	P.O.	—	—	No	—	—	No	—	—
B	saline	I.P.	No	Yes	Yes	Yes	Yes	—	—	—
50% B-50% PVP	distilled water	P.O.	—	—	No	No	Yes	Yes	—	—
50% B-50% PVP	distilled water	I.P.	—	—	No	—	—	—	—	—

(1) PVP=polyvinylpyrrolidone

(2) Saline=saline solution containing 1% carboxymethylcellulose and 0.1% Tween 80

(3) P.O.=oral; I.P.=intraperitoneal

A significant reduction in gastric glandular mucosal lesions at 80 and 160 mg./kg. is obtained with drug B — PVP formulations via the oral route. Unformulated drug B is comparable to carbenoxolone via the intraperitoneal route.

5 The effect of the products of this invention on renal excretion of water and electrolytes in rats is determined in the following manner:

Rat Diuretic Assay:

The water load (25 ml./kg.) or water load-containing drug is administered orally to each of three groups of two rats. Urine is collected for 5 hours and the samples from each group are analyzed by standard flame photometric techniques for sodium and potassium content. Urinary volume (ml./kg./5 hr.), sodium excreted (mEq./kg./5 hr.), potassium excreted (mEq./kg./5 hr.), and the sodium-potassium ratio is calculated for each group. The sodium/potassium ratio is modified by raising the denominator to the 1.3 power to yield a measure which is independent of the sodium/volume and potassium/volume ratios. Dose-response regression lines are calculated by combining data from all trials using water controls as zero dose.

Effect of Carbenoxolone and PVP formulated Drug B on the Renal Excretion of Water and Electrolytes and the Na/K Ratio in the Rat

	Carbenoxolone	50% Drug B— 50% PVP Formulation
Volume (ml./kg./5 hrs.)	↓ ↓	(↓)
Na (mEq./kg./5 hrs.)	↓ ↓	(↑)
K (mEq./kg./5 hrs.)	(↑)	(↑)
Na/K	↓ ↓ ↓	no effect
[Na] (meq./l.)	(↓)	↓ ↓
[K] (meq./l.)	↑ ↑ ↑	↓

The number of arrows indicate the magnitude of the effect; brackets () indicate a non-significant effect.

5 In water loaded rats, with increasing dose, carbenoxolone causes a moderate decrease in urinary volume and sodium, a marked decrease in the sodium/potassium ratio and a marked increase in potassium concentration, a slight but non-significant increase in urinary potassium and a decrease in urinary sodium concentration. In contrast, formulated Drug B caused a moderate increase in urinary sodium concentration, a slight increase in potassium concentration, and a slight but non-significant increase 5 in both urinary sodium and potassium and a decrease in urinary volume. It had no effect on the sodium/potassium ratio. The rate of increase in urinary potassium concentration with increasing doses of carbenoxolone is significantly greater than with formulated Drug B. The rate of decrease in urinary volume with dose is significantly greater with carbenoxolone than with formulated Drug B.

10 Their effect on gastric acid output in pylorus-ligated (i.e. Shay) rats is determined by the following procedure.

Shay Rat:

20 Forty-eight hours before surgery female rats (Charles River 'C—D strain; 100—140 gms.) are individually caged and taken off normal food. Each animal is given two sugar cubes and water *ad libitum* to effect emptying of the stomach. Drug or carrier is 20 administered intraperitoneally and three hours later, under ether anesthesia, the abdomen is shaved and opened along the linear alba. After exposing and ligating the pylorus, the incision is closed and the animal is returned to its cage and allowed to regain consciousness. Three hours later the animal is sacrificed by cervical dislocation, the abdomen reopened, the distal esophagus clamped, and the stomach excised. The 25 stomach is cut open and the contents washed into a beaker with one ml. of deionized water. The volume of gastric juice is recorded following centrifugation. Excessively dirty (greater than 0.5 ml. of solids) or bloody samples are discarded. The acidity of one ml. of gastric juice is determined by titration with a standardized NaOH (0.1N) 30 solution using phenolphthalein as an indicator and total acid output (μeqH^+ /100 gms. body weight/3 hours) is calculated. A non-paired *t* test is used to compare the means of the control and tested groups. Dixon *et al.*, *Technometrics*, X, 83—98, 1968.) Carbenoxolone and Drug B at 40 mg./kg. body weight consistently reduced gastric acid output in the three hour Shay rat. At 80 mg./kg., carbenoxolone, in contrast to Drug B, significantly decreased acid output in the Shay rat; N-[2-(2-hydroxyethyl-aminoethyl]-3 β -acetoxy-18 β -olean-12-en-30-amide and N-(3 β -acetoxy-18 β -olean-12-en-30-oyl)-L-histidine, methyl ester exhibit no effect upon acid output in the Shay rat.

35 The following Examples are given for a better explanation of the invention and not for limiting the scope of the invention.

EXAMPLE I.

N-(2-Hydroxyethyl)-3 β -Hydroxy-18 β -Olean-12-En-30-AmideA. 3 β -Hydroxy-18 β -olean-12-en-30-oic acid.

5 Eighty grams (0.169 M) of 18 β -glycyrrhetic acid in 1500 ml. of glacial acetic acid is hydrogenated at 50°C. using 20 g. of platinum oxide. The reaction is allowed to proceed for 3 hours at a pressure of 350 psi. Additional solvent is added to the reaction in an attempt to dissolve some of the product which precipitates. The catalyst is filtered and thoroughly washed with chloroform. Concentration of the combined filtrates followed by recrystallization of the solid residue from acetic acid gives 35.4 g., 45.6% of the title product; m.p. 319°—321°C. Ruzicka *et al.*, *Helv. Chim. Acta* 20, 1271 (1937) report m.p. 330°C.

B. 3 β -Acetoxy-18 β -olean-12-en-30-oic acid.

15 To a solution of 53.8 g. (0.120 M) of 3 β -hydroxy-18 β -olean-12-en-30-oic acid in 615 ml. of pyridine is added 615 ml. of acetic anhydride. The reaction is refluxed for one hour, cooled and stirred at room temperature for twenty-three hours. It is acidified with 10% hydrochloric acid and the resulting precipitate filtered and dissolved in chloroform. The chloroform solution is washed with water, dried over sodium sulfate and treated with activated charcoal. Concentration of the solution gives a solid which is recrystallized from methanol-chloroform to give 50.8 g., 85% of the acetoxy derivative; m.p. 300°—302°C. Corey *et al.*, *J. Am. Chem. Soc.* 81, 1745 (1959) report m.p. 305°—307°C.

C. 3 β -Acetoxy-18 β -olean-12-en-30-oyl chloride.

25 A solution of 42.0 g. (0.0843 M) of 3 β -acetoxy-18 β -olean-12-en-30-oic acid in 400 ml. of thionyl chloride is stirred at 50°C. for one hour. The excess thionyl chloride is removed under reduced pressure and the residue recrystallized from methylene chloride-hexane to give 37.9 g., 87% of the desired acid chloride; m.p. 245.5°—247.5°C. Ruzicka *et al.*, *Helv. Chim. Acta* 22, 195 (1939) report m.p. 248°—251°C.

D. N-(2-Hydroxyethyl)-3 β -acetoxy-18 β -olean-12-en-30-amide.

30 A solution of 10.45 g. (0.0202 M) of 3 β -acetoxy-18 β -olean-12-en-30-oyl chloride in 75 ml. of methylene chloride is added dropwise with stirring to a solution of 126 ml. (2.02 M) of 2-aminoethanol in 55 ml. of methylene chloride.

The reaction is stirred at room temperature for 17 hours and then washed successively with 10% hydrochloric acid, sodium bicarbonate solution and water. The organic layer is dried over sodium sulfate and concentrated to dryness to give 10.8 g., 98.5% of the intermediate acetate; m.p. 239°—240°C.

E. Hydrolysis of Intermediate Acetate.

40 A solution of 10.28 g. (0.0188 M) of acetate in 100 ml. of methanol and 535 ml. of 10% KOH/MeOH is stirred at room temperature for eighteen hours and then concentrated to dryness, acidified with 10% hydrochloric acid and extracted with methylene chloride. The combined organic extracts are dried over sodium sulfate and concentrated to dryness. Recrystallization of the residue yields 7.54 g., 80.3% of the title amide product; m.p. 245°—247°C.

EXAMPLE II.

1-(3 β -Acetoxy-18 β -Olean-12-En-30-Oyl)-4-(2-Hydroxyethyl)Piperazine

45 To a solution of 5.20 g. (0.0386 M) of piperazine ethanol in 100 ml. of methylene chloride is added dropwise with stirring 10.0 g. (0.0193 M) of acid chloride (Example I—C). A precipitate forms approximately five minutes after the acid chloride is added. The reaction mixture is stirred at room temperature for 15 hours and then made basic with 50% sodium hydroxide. The basic mixture is extracted with methylene chloride and the combined organic extracts washed with water, dried over sodium sulfate and treated with activated charcoal. Removal of the solvent and recrystallization of the residue from acetone affords 9.15 g., 77.6% of the title product; m.p. 234°—235°C.

50 The hydrochloride salt is prepared by bubbling hydrogen chloride gas into a solution of the title product in chloroform at 10°—15°C. The salt is precipitated by addition of ether, and then filtered and dried. It is recrystallized from chloroform-ether; m.p. 320°—323°C.

5

10

15

20

25

30

35

40

45

50

55

EXAMPLE III.

N-[3-[Bis-(2-Hydroxyethyl)Amino]Propyl]-3 β -Acetoxy-18 β -Olean-12-En-30-Amide

5 A solution of 7.7 g. (0.048 M) of N-(3-aminopropyl)diethanolamine in 50 ml. of methylene chloride is treated dropwise with 10.0 g. (0.019 M) of 3 β -acetoxy-18 β -olean-12-en-30-oyl chloride in 50 ml. of methylene chloride. The reaction is stirred at room temperature for 3 hours and then made basic with 50% sodium hydroxide. The mixture is extracted with methylene chloride and the combined organic extracts washed with water, dried over sodium sulfate, and treated with activated charcoal. The solvent is removed and the residue triturated with ether to give a solid which is recrystallized from acetone yielding 7.8 g., 65% of product; m.p. 192°—194°C.

5

The hydrochloride salt is prepared according to the procedure of Example II but using methylene chloride in place of chloroform as solvent; m.p. 282°—283°C.

10 The title compound is hydrolyzed to its 3 β -hydroxy derivative by the procedure of Example V—B.

10

15

EXAMPLE IV.

N-[3-(2-Hydroxyethylamino)Propyl]-3 β -Acetoxy-18 β -Olean-12-En-30-Amide

20 To a solution of 3.77 g. (0.032 M) of N-(β -hydroxyethyl)-1,3-diamino-propane in 50 ml. of methylene chloride is added dropwise with stirring 7.0 g. (0.013 M) of the acid chloride of Example I—C in 75 ml. of methylene chloride. The reaction mixture is stirred at room temperature for 20 hours and made basic with 50% sodium hydroxide. The methylene chloride layer is removed, washed with water and dried over sodium sulfate. Removal of the solvent and trituration of the residue with ether gives the product as a solid. Recrystallization of the solid from acetone affords 6.15 g., 79.1% of product; m.p. 188°—189°C.

20

25

EXAMPLE V.

1-(3 β -Hydroxy-18 β -Olean-12-En-30-Oyl)-4-Methylpiperazine HydrochlorideA. 1-(3 β -Acetoxy-18 β -olean-12-en-30-oyl)-4-methylpiperazine

30 To a solution of 10.5 g. (0.0202 M) of 3 β -acetoxy-18 β -olean-12-en-30-oyl chloride in 100 ml. of methylene chloride is added 4.1 g. (0.040 M) of 1-methylpiperazine. The reaction mixture is stirred at room temperature for 19 hours and then washed successively with dilute hydrochloric acid, aqueous sodium bicarbonate and water. The organic layer is separated, dried over sodium sulfate and concentrated to give 10.9 g., 93.7% of the acetate; m.p. 198°—200°C.

30

35

B. Hydrolysis of the Acetate

35 The acetate 8.0 g. (0.014 M) is stirred in 528 ml. of 10% KOH/MeOH at room temperature for 40 hours. The reaction mixture is then concentrated to dryness, acidified with 10% hydrochloric acid and extracted with methylene chloride. The combined organic extracts are dried over sodium sulfate, concentrated to dryness and the resulting solid recrystallized from methanol yielding 5.2 g., 65.8% of the title piperazine; m.p. 324°—325°C.

40

EXAMPLE VI.

N-[2-(2-Hydroxyethylamino)ethyl]-3 β -Acetoxy-18 β -Olean-12-En-30-Amide

45 To a solution of N-(2-hydroxyethyl)ethylenediamine 2.6 g. (0.025 M) in 50 ml. of methylene chloride is added 5.0 g. (0.01 M) of 3 β -acetoxy-18 β -olean-12-en-30-oyl chloride (Example I—C) in 50 ml. of methylene chloride over a period of 15 minutes. The reaction is stirred at room temperature for 4 hours and then made basic with 25% sodium hydroxide solution. The organic layer is separated, washed with water and dried over sodium sulfate. Concentration of the solution gives a solid which is recrystallized from acetone yielding 2.49 g., 42.5% of product; m.p. 180°—182°C.

45


50

50 The hydrochloride salt, formed by bubbling hydrogen chloride into a methylene chloride solution of the base, precipitates from solution. It is filtered, dried and recrystallized from ethanol; m.p. 318°—320°C.

EXAMPLE VII

A. The 3β -acyl-11-deoxoglycyrrhetic acid amides listed below are prepared from the appropriate amine $\text{HNR}_2\text{R}'_3$ and the appropriate 3β -acyl-11-deoxoglycyrrhetic acid chlorides of Example I—C and Preparation A. (R'_3 = hydrogen and R_3) by the procedure of Example VI.

5



R_1	R_2	R_3'
CH_3CO	H	CH_3
CH_3CO	H	C_2H_5
CH_3CO	H	i- C_3H_7
CH_3CO	H	n- C_4H_9
CH_3CO	CH_3	CH_3
CH_3CO	n- C_3H_7	n- C_3H_7
CH_3CO	H	$(CH_2)_3OH$
CH_3CO	H	$(CH_2)_4OH$
CH_3CO	CH_3	CH_2CH_2OH
CH_3CO	C_2H_5	CH_2CH_2OH
CH_3CO	CH_3CH_2OH	CH_2CH_2OH
CH_3CO	$CH_2CH(OH)CH_3$	$CH_2CH(OH)CH_3$
CH_3CO	CH_3	$CH_2CH(OH)CH_3$
CH_3CH_2CO	H	H
CH_3CH_2CO	H	n- C_3H_7
CH_3CH_2CO	CH_3	CH_3
CH_3CH_2CO	CH_3	n- C_3H_7
CH_3CH_2CO	H	CH_2CH_2OH
CH_3CH_2CO	H	$CH(C_2H_5)CH_2OH$
CH_3CH_2CO	CH_3	CH_2CH_2OH
CH_3CH_2CO	C_2H_5	CH_2CH_2OH
CH_3CH_2CO	n- C_4H_9	CH_2CH_2OH
CH_3CH_2CO	$(CH_2)_3OH$	$(CH_2)_3OH$
$CH_3(CH_2)_2CO$	H	H
$CH_3(CH_2)_2CO$	H	C_2H_5
$CH_3(CH_2)_2CO$	CH_3	CH_3
$CH_3(CH_2)_2CO$	n- C_4H_9	n- C_4H_9
$CH_3(CH_2)_2CO$	H	CH_2CH_2OH
$CH_3(CH_2)_2CO$	H	$CH_2CH(OH)CH_3$
$CH_3(CH_2)_2CO$	CH_3	CH_2CH_2OH
$CH_3(CH_2)_2CO$	C_2H_5	$(CH_2)_4OH$

R_1	R_2	R_3'
$CH_3(CH_2)_2CO$	CH_2CH_2OH	CH_2CH_2OH
$CH_3(CH_2)_3CO$	H	H
$CH_3(CH_2)_3CO$	H	C_6H_5
$CH_3(CH_2)_3CO$	C_2H_5	C_2H_5
$CH_3(CH_2)_3CO$	H	$(CH_2)_3OH$
$CH_3(CH_2)_3CO$	$(CH_2)_5OH$	$(CH_2)_3OH$
$CH_3(CH_2)_3CO$	C_2H_5	$(CH_2)_5OH$
$CH_3(CH_2)_4CO$	H	H
$CH_3(CH_2)_4CO$	H	$i-C_4H_9$
$CH_3(CH_2)_4CO$	H	C_2H_5
$CH_3(CH_2)_4CO$	CH_3	$n-C_6H_7$
$CH_3(CH_2)_4CO$	CH_3	$i-C_3H_7$
$CH_3(CH_2)_4CO$	H	CH_2CH_2OH
$CH_3(CH_2)_4CO$	CH_2CH_2OH	CH_2CH_2OH
$CH_3(CH_2)_4CO$	H	$(CH_2)_4OH$
$CH_3(CH_2)_4CO$	$(CH_2)_4OH$	$(CH_2)_4OH$
$CH_3(CH_2)_4CO$	CH_3	CH_2CH_2OH
CH_3CO	H	$(CH_2)_2NH(CH_2)_3OH$
CH_3CO	H	$(CH_2)_3NH(CH_2)_4OH$
CH_3CO	H	$(CH_2)_2N(CH_2)_4OH$
CH_3CO	H	$(CH_2)_4N(CH_2CH_2OH)_2$
CH_3CO	H	$(CH_2)_4NH(CH_2)_4OH$
CH_3CH_2CO	H	$(CH_2)_3NH(CH_2CH_2OH)$
CH_3CH_2CO	H	$(CH_2)_4N(CH_2CH_2OH)_2$
$CH_3(CH_2)_2CO$	H	$(CH_2)_3N(CH_2CH_2CH_2OH)_2$
$CH_3(CH_2)_4CO$	H	$(CH_2)_2NH(CH_2)_4OH$
CH_3CO		$CH_2CH_2NHCH_2CH_2$
CH_3CO		$CH_2CH_2N(C_2H_5)CH_2CH_2$
CH_3CO		$CH_2CH_2N(n-C_4H_9)CH_2CH_2$
CH_3CO		$CH_2CH_2N[(CH_2)_4OH]CH_2CH_2$
CH_3CO		$CH_2CH_2N(COOCH_3)CH_2CH_2$
CH_3CO		$CH_2CH_2N(COO-n-C_8H_7)CH_2CH_2$
CH_3CO		$CH_2CH_2CH_2CH_2$
CH_3CO		$CH_2CH_2CH_2CH_2CH_2$
CH_3CO		$CH(CH_3)CH_2CH_2CH_2CH_2CH(CH_3)$
CH_3CH_2CO		$CH_2CH_2NHCH_2CH_2$
CH_3CH_2CO		$CH_2CH_2N(CH_3)CH_2CH_2$
CH_3CH_2CO		$CH_2CH_2N(CH_2CH_2OH)CH_2CH_2$
CH_3CH_2CO		$CH_2CH_2N(COOCH_3)CH_2CH_2$
CH_3CH_2CO		$CH_2CH_2CH_2CH_2$
CH_3CH_2CO		$CH_2CH_2CH_2CH_2CH_2$
CH_3CH_2CO		$CH(CH_3)CH_2CH_2CH_2CH_2CH(CH_3)$
$CH_3(CH_2)_2CO$		$CH_2CH_2N(CH_3)CH_2CH_2$
$CH_3(CH_2)_2CO$		$CH_2CH_2N(CH_2CH_2OH)CH_2CH_2$
$CH_3(CH_2)_2CO$		$CH_2CH_2CH_2CH_2$
$CH_3(CH_2)_2CO$		$CH_2CH_2CH_2CH_2CH_2$
$CH_3(CH_2)_3CO$		$CH_2CH_2NHCH_2CH_2$
$CH_3(CH_2)_3CO$		$CH_2CH_2N(i-C_3H_7)CH_2CH_2$
$CH_3(CH_2)_3CO$		$CH_2CH_2N(CH_2CH_2CH_2OH)CH_2CH_2$
$CH_3(CH_2)_3CO$		$CH_2CH_2N(COOCH_3)CH_2CH_2$
$CH_3(CH_2)_4CO$		$CH_2CH_2N(n-C_3H_7)CH_2CH_2$

R ₁	R ₂	R ₃ '
CH ₃ (CH ₂) ₄ CO	CH ₂ CH ₂ N(COO-n-C ₄ H ₉)CH ₂ CH ₂	
CH ₃ (CH ₂) ₄ CO	CH ₂ CH ₂ CH ₂ CH ₃	
H	CH ₂ CH ₂ N(CH ₂ CH ₂ OH)CH ₂ CH ₂	
HOOC-(CH ₂) ₂ -CO	CH ₂ CH ₂ N(CH ₂ CH ₂ OH)CH ₂ CH ₂	
CH ₃ CO	H	CH(C ₂ H ₅)CH ₂ OH
CH ₃ CO	H	CH(CH ₃)CH(OH)CH ₃
CH ₃ CO	H	CH ₂ CH ₂ OC ₂ H ₅
CH ₃ CO	H	(CH ₂) ₃ OC ₂ H ₅
CH ₃ CO	H	(CH ₂) ₄ OC ₂ H ₅
CH ₃ CO	CH ₂ CH ₂ OC ₂ H ₅	CH ₂ CH ₂ OC ₂ H ₅
CH ₃ CO	CH ₂ CH(OC ₂ H ₅)CH ₃	CH ₂ CH(OC ₂ H ₅)CH ₃
CH ₃ CO	CH ₃	CH ₂ CH ₂ OC ₂ H ₅
CH ₃ CO	C ₄ H ₉	CH ₂ CH ₂ OC ₂ H ₅
CH ₃ CH ₂ CO	H	CH ₂ CH ₂ OC ₂ H ₅
CH ₃ CH ₂ CO	(CH ₂) ₃ OC ₂ H ₅	(CH ₂) ₃ OC ₂ H ₅
CH ₃ (CH ₂) ₂ CO	H	CH ₂ CH ₂ OC ₂ H ₅
CH ₃ (CH ₂) ₂ CO	C ₂ H ₅	(CH ₂) ₄ OC ₂ H ₅
CH ₃ (CH ₂) ₃ CO	H	(CH ₂) ₃ OC ₂ H ₅
CH ₃ (CH ₂) ₄ CO	(CH ₂) ₄ OC ₂ H ₅	(CH ₂) ₄ OC ₂ H ₅

The last thirteen esters tabulated above are only intermediates and not final products.

5 B. Hydrolysis of the 3-acyloxy groups of the above compounds according to the procedure of Example V—B provides the corresponding 3-hydroxy derivatives. 5

EXAMPLE VIII.

Hemisuccinate of N-(2-Hydroxyethyl)-3,6-Hydroxy-18 β -Olean-12-En-30-Amide

A. 3,6-(β -Carbomethoxypropionyloxy)-18 β -olean-12-en-30-oic acid

10 A solution of 11-deoxoglycyrheticin acid (5.0 g.) in pyridine (20 ml.) is treated with a solution of β -carbomethoxypropionyl chloride (3 ml.) in pyridine (50 ml.). The reaction mixture is allowed to stand for four days then then poured into water (100 ml.). The product is extracted with ether (3 \times 250 ml.), the combined ethereal extracts dried ($MgSO_4$) and evaporated under reduced pressure. The residue is recrystallized from methanol-water. 10

15 Similarly, the corresponding 3,6-(γ -carbomethoxybutyryloxy)-derivative is prepared substituting γ -carbomethoxybutyryl chloride for β -carbomethoxypropionyl chloride. 15

20 B. A solution of 3 β -(β -carbomethoxypropionyloxy)-18 β -olean-12-en-30-oyl chloride (11.54 g., 0.02 M, prepared from the precursor acid by the procedure of Example I—C) in methylene chloride (75 ml.) is added dropwise with stirring to a solution of 2-aminoethanol (2.0 M) in methylene chloride (50 ml.) and the mixture stirred at room temperature for 17 hours. It is then washed successively with 10% hydrochloric acid, sodium bicarbonate solution and water and dried (Na_2SO_4). The product is recovered by removal of the solvent under reduced pressure. 20

25 C. Hydrolysis of the ester is accomplished by treating a solution of the ester in N,N-dimethylformamide (15 ml./1.0 mM of ester) with lithium iodide (1.0 g./1.0 mM of ester) under reflux for 12 hours. The reaction mixture is cooled, poured into water and the product recovered by filtration if solid or by extraction with methylene chloride. 25

30 In this manner, the hemisuccinate and hemiglutamate esters of the amides of Examples I—VII are prepared by substituting the appropriate 3 β -carbomethoxyalkanoyloxy-11-deoxoglycyrheticin acid chloride for the 3 β -alkanoyloxy-11-deoxo-glycyrheticin acid chloride of the Examples. 30

EXAMPLE IX.

N-(3 β -Acetoxy-18 β -Olean-12-En-30-Oyl)L-Histidine Methyl Ester

5 A solution of 15.0 g. (0.0291 M) of 3 β -acetoxy-18 β -olean-12-en-30-oyl chloride in 75 ml. of methylene chloride is added dropwise to a hazy solution of 7.04 g. (0.0291 M) of L-histidine methyl ester dihydrochloride and 11.3 g. (0.0872 M) of N,N-diisopropylethylamine in 175 ml. of methylene chloride. The reaction mixture is stirred at room temperature for five days and then washed with water, treated with activated charcoal and dried over magnesium sulfate. Concentration of the solution leaves an oily solid which is crystallized with hot methanol and, subsequently, recrystallized from chloroform-methanol to give 5.6 g. of unidentified by-product; m.p. 262°-263°C.

10 and impure product. The impure product is recrystallized from chloroform-methanol yielding 11.57 g., 61.5% of the title product; m.p. 207°-209°C.

5


10

15

EXAMPLE X.

15 Repetition of the procedure of Example IX but using the appropriate amino acid in place of L-histidine methyl ester dihydrochloride and the appropriate 3 β -acyl-11-deoxoglycyrhetic acid chlorides affords the following compounds. Sufficient N,N-diisopropylethylamine is used in a given reaction to neutralize the acid (HCl) by-product plus any acid introduced with the amino acid reactant.

15



R ₁	R ₄	R ₅
CH ₃ CO	H	OCH ₃
CH ₃ CO	CH ₃	OC ₂ H ₅
CH ₃ CO	C ₂ H ₅	OCH ₃
CH ₃ CO	CH ₂ CH(CH ₃) ₂	NH ₂
CH ₃ CO	CH ₂ OH	O-(n-C ₄ H ₉)
CH ₃ CO	CH(OH)CH ₃	OCH ₃
CH ₃ CO	CH ₂ -4-(or 5)-Im*	OCH ₃
CH ₂ CO	C ₂ H ₅ -CH ₃	OC ₂ H ₅
CH ₃ CO	4-HOC ₆ H ₄ -CH ₃	OCH ₃
CH ₃ CO	COOC ₂ H ₅	OC ₂ H ₅
CH ₃ CO	COO-n-C ₃ H ₇	O-(n-C ₃ H ₇)
CH ₃ CO	CH ₂ COOH	OCH ₃
CH ₃ CO	CH ₂ COOH	NH ₂
CH ₃ CO	CH ₂ CH ₂ COOH	OC ₂ H ₅
CH ₃ CO	CH ₂ CH ₂ NH ₂	OCH ₃
CH ₃ CO	CH ₃	OH
CH ₃ CO	(CH ₃) ₄ NH ₂	OCH ₃
CH ₃ CO	CH ₃ CH ₂ C(=O)NH ₂	OCH ₃
CH ₃ CO	CH ₂ CONH ₂	OC ₂ H ₅
CH ₃ CO	(CH ₃) ₃ NHC(=NH)NH ₂	NH ₂
CH ₃ CO	(CH ₃) ₃ NHC(=NH)NH ₂	OCH ₃
CH ₃ CO	(CH ₃) ₃ NHCONH ₂	OCH ₃

R_1	R_4	R_5
CH_3CO	$CH_2(3\text{-indolyl})$	OCH_3
CH_3CO	CH_3	$N(CH_3)_2$
CH_3CO	H	$N(n-C_3H_7)_2$
CH_3CO	CH_2OH	$N(C_6H_5)_2$
CH_3CO	$C_6H_5CH_2$	NH_2
CH_3CO	$(CH_2)_4NH_2$	$N(CH_3)_2$
CH_3CH_2CO	H	OC_6H_5
CH_2CH_2CO	CH_2SH	OCH_3
CH_3CH_2CO	$CH_2CH_2SCH_3$	OCH_3
CH_3CH_2CO	$n-C_6H_5$	NH_2
CH_3CH_2CO	CH_2OH	$N(C_6H_5)_2$
CH_3CH_2CO	$CH_2-4\text{-}(or 5\text{-})Im^*$	OCH_3
CH_3CH_2CO	$C_6H_5CH_2$	$O-(n-C_3H_7)$
CH_3CH_2CO	$3,4\text{-}(HO)_2C_6H_3-CH_2$	OCH_3
CH_3CH_2CO	$(CH_2)_3NHCONH_2$	$N-(i-C_3H_7)_2$
CH_3CH_2CO	$CH_2CH_2CONH_2$	OCH_3
CH_3CH_2CO	$CH_2CH_2NH_2$	OC_6H_5
$CH_3(CH_2)_2CO$	CH_3	$N-(n-C_3H_7)_2$
$CH_3(CH_2)_2CO$	$CH_2CH_2SCH_3$	OCH_3
$CH_3(CH_2)_2CO$	$COO-(n-C_4H_9)$	$O(n-C_4H_9)$
$CH_3(CH_2)_2CO$	$COOC_2H_5$	OC_2H_5
$CH_3(CH_2)_2CO$	$C_6H_5CH_2$	NH_2
$CH_3(CH_2)_2CO$	$3,5-Br_2-4-HOC_6H_2-CH_2$	OCH_3
$CH_3(CH_2)_3CO$	$n-C_6H_5$	NH_2
$CH_3(CH_2)_3CO$	$CH_2(3\text{-indolyl})$	$N-(C_6H_5)_2$
$CH_3(CH_2)_3CO$	$CH_2CH_2COOCH_3$	OCH_3
$CH_3(CH_2)_3CO$	$CH_2CH_2COO-n-C_4H_9$	$O-n-C_4H_9$
$CH_3(CH_2)_3CO$	$CH_2COOC_2H_5$	OC_2H_5
$CH_3(CH_2)_3CO$	CH_2COOCH_3	NH_2
$CH_3(CH_2)_4CO$	$CH(CH_3)_2$	OC_6H_5
$CH_3(CH_2)_4CO$	$n-C_6H_5$	OC_2H_5
$CH_3(CH_2)_4CO$	H	$N(n-C_4H_9)_2$
$CH_3(CH_2)_4CO$	$CH_2CH_2SCH_3$	$N(CH_3)_2$

* Im=imidazolyl

Hydrolysis of the above products as described in Example V—B affords the corresponding derivatives wherein R_1 is H, and all ester and amide values of R_4 and COR_5 are converted to carboxy.

5

EXAMPLE XI.

Hemisuccinate of 1-(3 β -Hydroxy-18 β -Olean-12-En-30-Oyl)-4-Methylpiperazine

The product of Example V (0.01 M) is dissolved in dry pyridine (30 ml.) and a solution of succinic anhydride (0.012 M) in dry pyridine (10 ml.) added, followed by dry triethylamine (5 ml.). The mixture is heated on a boiling water bath for ten hours and then poured into excess dilute hydrochloric acid and ice. The product is filtered off and washed with water. It is then dissolved in chloroform, the solution repeatedly extracted with dilute hydrochloric acid followed by water. The chloroform solution is then dried (Na_2SO_4) and evaporated to give the product.

10

In like manner, the hemiglutamate is prepared substituting glutaric anhydride for succinic anhydride.

Repetition of this procedure but using the products of Example VII which contain no hydroxyalkyl group in the amide moiety affords the hemisuccinates and hemiglutarates of the compounds.

EXAMPLE XII.

N-[3 β -(β -Carbomethoxypropionyloxy)-18 β -Olean-12-En-30-Oyl]Serine, Methyl Ester (intermediate)

A solution of 3 β -(β -carbomethoxypropionyloxy)-18 β -olean-12-en-30-oyl chloride (11.54 g., 0.02 M), i.e. the methyl ester of the hemisuccinate of 11-deoxoglycyrhetic acid chloride, in methylene chloride (75 ml.) is added dropwise to a solution of serine methyl ester (2.38 g., 0.02 M) and N,N-diisopropylethylamine (2.58 g., 0.02 M) in methylene chloride (150 ml.). The reaction mixture is stirred for five days at room

15

20

25

temperature and then washed with water, decolorized with activated charcoal and dried over magnesium sulfate. Concentration of the solution affords the product.

Repetition of this procedure but using 3β -(γ -carbomethoxybutyryloxy)- 18β -olean-12-en-30-oyl chloride as the O-acylating agent provides N-[3β -(γ -carbomethoxybutyryloxy)- 18β -olean-12-en-30-oyl]serine, methyl ester.

5

EXAMPLE XIII.

N-[3β -(β -Carboxypropionyl)- 18β -Olean-12-En-30-Oyl] Serine

The title dimethyl ester product of Example XII (0.659 g., 1 mM) in N,N-dimethylformamide (75 ml.) is treated with anhydrous lithium iodide (10 g.) and the solution heated at reflux for 12 hours. The reaction mixture is cooled, poured into water and the product recovered by filtration or by extraction with methylene chloride.

Similarly, the remaining diester of Example XII is hydrolyzed to the corresponding product N-[3β -(γ -carboxybutyryloxy)- 18β -olean-12-en-30-oyl] serine.

10

EXAMPLE XIV.

N-[3β -(β -Carboxypropionyloxy)- 18β -Olean-12-En-30-Oyl] Lysine

The procedure of Example XII is repeated but using the ϵ -carbobenzoxy derivative of lysine methyl ester in place of serine methyl ester. The product thus obtained is taken up in ethanol and treated with hydrogen in the presence of 5% palladium on charcoal to remove the protective carbobenzoxy group. Filtration of the catalyst followed by removal of the solvent gives the methyl ester of the hemisuccinate.

Hydrolysis of the dimethyl ester according to the procedure of Example VIII—C, using, of course, twice the proportion of lithium iodide produces the title product.

15

EXAMPLE XV.


N-[3β -(β -Carboxypropionyloxy)- 18β -Olean-12-En-30-Oyl]

Glutamic Acid, Methyl Ester

Following the procedure of Example VIII—A, but using β -carbobenzoxy propionyl chloride produces 3β -(β -carbobenzoxypropionyloxy)- 18β -olean-12-en-30-oic acid. The acid chloride is then prepared by the procedure of Example I—C.

Methyl γ -amino- γ -carbobenzoxy-butyrate,

20



25

is then treated with the above-produced acid chloride by the procedure of Example XII to give the dibenzyl ester of the title product.

The benzyl groups are removed using hydrogen, 5% palladium on carbon in ethanol according to Example XIV to give the title product.

30

EXAMPLE XVI.

N-[3β -(β -Carboxypropionyloxy)- 18β -Olean-12-En-30-Oyl] Cysteine

The procedure of Example XII is repeated but using the methyl ester of S-benzylcysteine in place of serine methyl ester. The N-[3β -(β -carbomethoxypropionyloxy)- 18β -olean-12-en-30-oyl] S-benzylcysteine, methyl ester thus produced is hydrolyzed by the procedure of Example XIII to the corresponding acid derivative.

35

Debenzylation is accomplished by treatment with hydrogen in the presence of Pd/C according to Example XIV to give the title product.

Repetition of this procedure using 3β -(γ -carbomethoxy butyryloxy)- 18β -olean-12-en-30-oyl chloride as acylating agent provides the hemiglutamate of the title compound.

40

EXAMPLE XVII.

N-[3β -(β -Carboxypropionyloxy)- 18β -Olean-12-En-30-Oyl] Arginine

This product is prepared from nitro arginine methyl ester hydrochloride and the methyl ester of the hemisuccinate of 11-deoxoglycyrhetic acid chloride by the procedure of Example XII. The N-[3β -(β -carbomethoxypropionyloxy)- 18β -olean-12-en-30-oyl] nitroarginine, methyl ester thus produced is converted to the corresponding arginine methyl ester by reaction with hydrogen and Pd/C as described in Example XIV.

45

Hydrolysis of the dimethyl ester with lithium iodide according to the procedure of Example XIII affords the title product.


50

In like manner, the hemiglutamate of the title product is prepared using the methyl ester of the hemiglutamate of 11-deoxoglycyrhetic acid chloride.

55

EXAMPLE XVIII.

Following the procedure of Examples VIII and XI—XVI, the compounds listed below are prepared from appropriate reactants.



n	R ₄	R ₅
2	CH(OH)CH ₃	OH
2	4-HOC ₆ H ₄ -CH ₂	OH
3	4-HOC ₆ H ₄ -CH ₂	OH
2	CH ₃ OH	N(C ₂ H ₅) ₂
3	CH ₃ OH	N(C ₂ H ₅) ₂
2	3,4-(HO) ₂ C ₆ H ₃ -CH ₂	OH
3	3,4-(HO) ₂ C ₆ H ₃ -CH ₂	OH
2	3,5-Br ₂ -4-HOC ₆ H ₃ -CH ₂	OH
2	COOH	OH
3	COOH	OH
2	CH ₂ COOH	OH
3	CH ₂ COOH	OH
2	CH ₂ COOH	NH ₂
2	CH ₂ CH ₂ COOH	OH
2	COOC ₂ H ₅	OH
2	COO-n-C ₄ H ₉	OH
2	CH ₂ COOC ₂ H ₅	OH
3	CH ₂ COOC ₂ H ₅	OH
2	CH ₂ CH ₂ COOCH ₃	OH
2	CH ₂ COOCH ₃	NH ₂
3	CH ₂ COOCH ₃	NH ₂
2	COOH	N(CH ₃) ₂
2	COOH	N-(n-C ₄ H ₉) ₂
2	CH ₂ -4-(or 5)-Im	OH
3	CH ₂ -4-(or 5)-Im	OH
2	CH ₂ CH ₂ NH ₂	OH
3	CH ₂ CH ₂ NH ₂	OH
2	(CH ₂) ₄ NH ₂	OH
2	(CH ₂) ₄ NH ₂	N(CH ₃) ₂
3	(CH ₂) ₄ NH ₂	N(CH ₃) ₂
2	CH ₂ CONH ₂	OH
3	CH ₂ CONH ₂	OH

n	R ₄	R ₅
2	CH ₂ CONH ₂	NH ₂
2	CH ₂ CH ₂ CONH ₂	OH
2	(CH ₂) ₃ CONH ₂	OH
2	(CH ₂) ₃ CONH ₂	NH ₂
2	(CH ₂) ₃ NHCONH ₂	OH
2	(CH ₂) ₃ NHCONH ₂	N(i-C ₃ H ₇) ₂
3	(CH ₂) ₃ NHCONH ₂	N(i-C ₃ H ₇) ₂
2	CH ₂ (3-indolyl)	OH
3	CH ₂ (3-indolyl)	OH
2	CH ₂ (3-indolyl)	N(C ₂ H ₅) ₂
2	H	OH
3	H	OH
2	H	NH ₂
2	H	N(n-C ₃ H ₇) ₂
3	H	N(n-C ₃ H ₇) ₂
2	CH ₃	OH
2	CH ₃	N(CH ₃) ₂
3	CH ₃	N(CH ₃) ₂
2	CH ₃	N(n-C ₃ H ₇) ₂
2	C ₂ H ₅	OH
2	n-C ₃ H ₇	NH ₂
3	n-C ₃ H ₇	NH ₂
2	CH ₂ CH(CH ₃) ₂	NH ₂
2	n-C ₄ H ₉	NH ₂
3	n-C ₄ H ₉	NH ₂
2	C ₆ H ₅ -CH ₂	OH
3	C ₆ H ₅ -CH ₂	OH
2	C ₆ H ₅ -CH ₂	NH ₂
2	CH ₂ CH ₂ SCH ₃	OH
3	CH ₂ CH ₂ SCH ₃	OH
2	CH ₂ CH ₂ SCH ₃	N(CH ₃) ₂
2	CH ₂ -4-(or 5)-Im	NH ₂
2	(CH ₂) ₃ NHC(=NH)NH ₂	OH
3	(CH ₂) ₃ NHC(=NH)NH ₂	OH
2	(CH ₂) ₃ NHC(=NH)NH ₂	NH ₂

EXAMPLE XIX.

Acid Addition Salt Formation

The appropriate 11-deoxoglycyrhelinamide of formulae I or II which contains a basic group is dissolved in a suitable solvent, e.g., chloroform, methylene chloride, ethanol, and an excess of the appropriate acid added to the solution. The product, if insoluble in the solvent, is recovered by filtration. The product, if soluble in the solvent, is recovered by addition of a non-solvent for the salt, e.g., ether, or by evaporation of the solvent under reduced pressure.

In this manner, the hydrochloride, hydrobromide, tartrate, citrate, acetate, propionate, butyrate, gluconate, benzoate, succinate, malate, maleate, fumarate, nitrate, sulfate, and oxalate salts of the products of Examples II—XVIII which contain a basic group are prepared.

EXAMPLE XX.

Metal Salt Formation

A mixture (solution or suspension) of the appropriate 11-deoxoglycyrhelinamide compound of formulae I or II in water is treated with one equivalent of the appropriate metal hydroxide for each carboxy group present. The mixture is stirred at room temperature until reaction is complete and the salt recovered by removal of the water, e.g., by freezedrying.

15

5

10

15

20

20

In this manner, the sodium and potassium salts of those compounds of Examples VIII, and XI—XVIII having at least one carboxy group are prepared.

The following Preparations illustrate the preparation of intermediates.

PREPARATION A.

5 3β -Acyloxy- 18β -Olean-12-En-30-Oic Acids
(via Acid Anhydride)

5

The procedure of Example I—B is repeated but using the appropriate acid anhydride in place of acetic anhydride to give the following 3β -acyl derivatives of 11-deoxoglycyrhetic acid:

10 propionyl
butyryl
isobutyryl
valeryl
caproyl

10

PREPARATION B.

15 3β -Acyloxy- 18β -Olean-12-En-30-Oic Acids
(via Acid Chloride)

15

A mixture of 11-deoxoglycyrhetic acid (0.1 mM), the appropriate acyl chloride (10 mM) and pyridine (10 mM) is heated on a water bath for 1.5 hours and then poured into water. The aqueous mixture is extracted with ether and the ether solution washed successively with dilute aqueous sodium hydroxide and hydrochloric acid and then dried (Na_2SO_4). Evaporation of the solvent affords the product which is recrystallized from a suitable solvent such as methanol-chloroform.

20

The following 3β -acyl derivatives are thus prepared:

25 acetyl
propionyl
caproyl

25

PREPARATION C.

30 3β -Acyloxy- 18β -Olean-12-En-30-Oyl Chlorides

30

The 3β -acyl derivatives of Preparations A and B derived from monocarboxylic acids are converted to their acid chlorides by the procedure of Example I—C.

PREPARATION D.

35 3β -(γ -Carbomethoxybutyryloxy)- 18β -Olean-12-En-30-Oyl Chloride


35

To a solution of 11-deoxoglycyrhetic acid (4.86 g.) in pyridine (20 ml.) is added γ -carbomethoxybutyryl chloride (3 ml.) in pyridine (50 ml.). The reaction mixture is allowed to stand for four days and is then poured into water (100 ml.). The aqueous mixture is extracted with ether (3 \times 250 ml.) and the combined ethereal extracts dried over magnesium sulfate. Evaporation of the ether gives the crude product which is recrystallized to constant melting point from methanol-water.

40 WHAT WE CLAIM IS:—


40

1. 11-Deoxoglycyrhetic acid derivatives having the formulae:



and

... I



... II

wherein

5 R_1 is hydrogen, alkanoyl having from two to six carbon atoms, or ω -carboxy-alkanoyl having a total of from four to five carbon atoms;

5 R_2 is hydrogen, alkyl having from one to four carbon atoms, or hydroxyalkyl having from two to four carbon atoms;

10 R_3' is alkyl having from one to four carbon atoms, hydroxyalkyl having from two to four carbon atoms, ω -(hydroxyalkylamino)alkyl or ω -[bis(hydroxyalkyl)amino]-alkyl both having from two to four carbon atoms in each alkyl moiety; or

15 R_2 and R_3' when taken together with the nitrogen atom to which they are attached are piperazine, N -alkylpiperazine having from one to four carbon atoms in the alkyl moiety, N -(ω -hydroxyalkyl)piperazine having from two to four carbon atoms in the alkyl moiety, N -(carbalkoxy)piperazine having from one to four carbon atoms in the alkoxy moiety, pyrrolidino, piperidino or 2,6-dimethylpiperidino;

15 with the proviso that when R_2 is alkyl or hydroxyalkyl, R_3' is other than ω -(hydroxyalkylamino)alkyl or ω -[bis(hydroxyalkyl)amino]-alkyl;

20 R_4 is hydrogen, alkyl having from one to four carbon atoms,

hydroxymethyl,

1-hydroxyethyl,

mercaptomethyl,

2-methylthioethyl,

4-(or 5)-imidazolylmethyl,

benzyl,

4-hydroxybenzyl,

3,4-dihydroxybenzyl,

3,5-dibromo-4-hydroxybenzyl,

carboxy,

5

10

15

20

25

30

35

40

45

30 carbalkoxy having from one to four carbon atoms in the alkoxy moiety, ω -carboxyalkyl having from one to two carbon atoms in the alkyl moiety, ω -(carbalkoxy)alkyl having from one to four carbon atoms in the alkoxy group and one to two carbon atoms in the alkyl group,

30 ω -aminoalkyl having from two to four carbon atoms in the alkyl moiety,

30 ω -carbamoylalkyl having from one to three carbon atoms in the alkyl moiety;

35 3-guanidinopropyl,

35 3-ureidopropyl, or

35 3-indolylmethyl;

40 R_5 is hydroxy, alkoxy having from one to four carbon atoms, amino or dialkylamino having from one to four carbon atoms in each alkyl moiety;

40 the pharmaceutically-acceptable metal salts of those compounds having at least one carboxy group; and

45 the pharmaceutically-acceptable acid addition salts of those compounds having a basic group.

45 2. An 11-deoxoglycyrheticin acid derivative according to claim 1, Formula I.

45 3. A compound according to claim 2, wherein R_1 is hydrogen and $-\text{NR}_2\text{R}'$ is N -(ω -hydroxyalkyl)piperazino.

4. A compound according to claim 2, wherein each of R_1 and R_2 is hydrogen and R_3' is hydroxyalkyl. 5. A compound according to claim 2, wherein R_1 is alkanoyl, R_2 is hydrogen and R_3' is ω -[bis(hydroxyalkyl)amino]alkyl. 5
6. A compound according to claim 2, wherein R_1 is alkanoyl, and $-NR_2R_3'$ is $N-(\omega\text{-hydroxyalkyl})$ piperazino. 7. A compound according to claim 2, wherein R_1 is ω -carboxyalkanoyl and $-NR_2R_3'$ is $4-(\omega\text{-hydroxyalkyl})$ piperazino. 10
8. A compound according to claim 2, wherein R_1 is alkanoyl, R_2 is hydrogen and R_3' is ω -(hydroxyalkyl)amino)alkyl. 10
9. A compound according to claim 2, wherein R_1 is ω -carboxyalkanoyl, and each of R_2 and R_3' is alkyl. 15
10. $1-(3\beta\text{-Hydroxy-}18\beta\text{-olean-12-en-30-oyl})-4-(2\text{-hydroxyethyl})$ piperazine, a compound according to claim 3, wherein $-NR_2R_3'$ is $4-(2\text{-hydroxyethyl})$ piperazino. 15
11. $N-(2\text{-Hydroxyethyl})-3\beta\text{-hydroxy-}18\beta\text{-olean-12-en-30-amide}$, a compound according to claim 4, wherein R_3' is 2-hydroxyethyl. 15
12. $N-[3\text{-[Bis-(2-hydroxyethyl)amino]propyl}]-3\beta\text{-acetoxy-}18\beta\text{-olean-12-en-30-amide}$, a compound according to claim 5, wherein R_1 is acetyl and R_3' is 3-[bis-(2-hydroxyethyl)amino]propyl. 20
13. $1-(3\beta\text{-Acetoxy-}18\beta\text{-olean-12-en-30-oyl})-4-(2\text{-hydroxyethyl})$ piperazine, a compound according to claim 6, wherein R_1 is acetyl and $-NR_2R_3'$ is $4-(2\text{-hydroxyethyl})$ piperazino. 20
14. $1-[3\beta\text{-(}\beta\text{-Carboxypropionyloxy)-}18\beta\text{-olean-12-en-30-oyl}]-4-(2\text{-hydroxyethyl})$ piperazine, a compound according to claim 7, wherein R_1 is carboxypropionyl and $-NR_2R_3'$ is $4-(2\text{-hydroxyethyl})$ piperazino. 25
15. $N-[2-(2\text{-Hydroxyethylamino)ethyl}]-3\beta\text{-acetoxy-}18\beta\text{-olean-12-en-30-amide}$, a compound according to claim 8, wherein R_1 is acetyl and R_3' is 2-(2-hydroxyethylamino)ethyl. 25
16. An 11-deoxoglycyrhetic acid derivative according to claim 1, Formula II. 30
17. A compound according to claim 16, wherein R_1 is acetyl, R_5 is hydroxy and R_4 is alkyl. 30
18. A compound according to claim 16, wherein R_1 is ω -carboxyalkanoyl, R_4 is ω -carboxyalkyl and R_5 is hydroxy. 35
19. A compound according to claim 16, wherein R_1 is alkanoyl, R_4 is 4-(or 5)-imidazolylmethyl and R_5 is alkoxy. 35
20. A compound according to claim 16, wherein R_1 is alkanoyl, R_4 is 3-guanidinopropyl and R_5 is alkoxy. 40
21. $N-(3\beta\text{-Acetoxy-}18\beta\text{-olean-30-oyl})$ alanine, a compound according to claim 17, wherein R_4 is methyl. 40
22. $N-(3\beta\text{-Acetoxy-}18\beta\text{-olean-12-en-30-oyl})$ histidine methyl ester, compound according to claim 18, wherein R_1 is β -carboxypropionyl and R_4 is β -carboxyethyl. 45
23. $N-(3\beta\text{-Acetoxy-}18\beta\text{-olean-12-en-30-oyl})$ histidine methyl ester, a compound according to claim 19, wherein R_1 is acetyl and R_5 is methoxy. 45
24. $N-(2\beta\text{-Acetoxy-}18\beta\text{-olean-12-en-30-oyl})$ arginine methyl ester, a compound according to claim 20, wherein R_1 is acetyl and R_5 is methoxy. 50
25. A method for the control of ulcers in animals other than humans which comprises administering to the animals a composition containing a diluent amount of a pharmaceutically-acceptable carrier and, as the essential active ingredient, a compound of Formula I or II as defined in claim 1 above and wherein R_3' can, in addition, also be a hydrogen atom. 50

STEVENS, HEWLETT & PERKINS,
Chartered Patent Agents,
5, Quality Court,
Chancery Lane,
London, W.C.2.